Sub clinical hyperthyroidism Nutritional, Metabolic, Endocrine
Conditions
Interventions
Treatment with carbimazole or placebo for 6 months.
Randomisation process will be done electronically using randomization codes with the help of medical statistician at the CRU (TTSH)
Sponsors
Tan Tock Seng Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of subclinical hyperthyroidism confirmed at least on two occasions (low serum TSH with normal FT4) and one normal FT3 levels within three months prior to the recruitment 2. Aged 21-85 years 3. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Sick euthyroid syndrome 2. Recent radioiodine therapy (within 1 year of screening visit) 3. Pregnant or breastfeeding patients 4. Acute medical illnesses such as infections and active cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levels of circulating endothelial progenitor cells (EPC), circulating endothelial cells (CEC), Hs CRP, ADMA, lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, Neutrophil lymphocyte ratio and monocyte lymphocyte ration in peripheral blood measured using an assay of blood sample at baseline and 6-months | — |
Secondary
| Measure | Time frame |
|---|---|
| At baseline and 6-months: 1. Anthropometry 1.1. Blood pressure (mmHg) 1.2. Weight (kg) 1.3. BMI (kg/m²) 2. Thyroid hormones, and endothelial markers such as EPC, CEC, ADMA measured by blood test 3. Cognitive assessments: 3.1. Mini mental state examination (MMSE) 3.2. Montreal cognitive assessment (MoCA) | — |
Countries
Singapore
Contacts
Public ContactShaikh Abdul Kader Kamaldeen Abdul Shakoor
Outcome results
None listed